Literature DB >> 21670185

Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Ching-Lan Lu1, Chia-Ying Liu, Yu-Tsung Huang, Chun-Hsing Liao, Lee-Jene Teng, John D Turnidge, Po-Ren Hsueh.   

Abstract

We studied the antimicrobial activity of fosfomycin against 960 strains of commonly encountered bacteria associated with urinary tract infection using standard agar dilution and disk diffusion methods. Species studied included 3 common species of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia; methicillin-susceptible and -resistant Staphylococcus aureus; and vancomycin-susceptible and resistant Enterococcus faecalis and E. faecium. MICs and inhibition zone diameters were interpreted in accordance with both the currently recommended Clinical and Laboratory Standards Institute (CLSI) criteria for urinary tract isolates of Escherichia coli and Enterococcus faecalis and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria for Enterobacteriaceae. Tentative zone diameter interpretive criteria were developed for species not currently published by CLSI or EUCAST. Escherichia coli was uniformly susceptible to fosfomycin, as were most strains of Klebsiella pneumoniae and Enterobacter cloacae. A. baumannii was resistant to fosfomycin, while the prevalence of resistance in P. aeruginosa and S. maltophilia was greatly affected by the choice of MIC breakpoint. New tentative zone diameter criteria for K. pneumoniae, E. cloacae, S. aureus, and E. faecium were able to be set, providing some interim laboratory guidance for disk diffusion until further breakpoint evaluations are undertaken by CLSI and EUCAST.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670185      PMCID: PMC3165352          DOI: 10.1128/AAC.00349-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii.

Authors:  L Martinez-Martinez; G Rodriguez; A Pascual; A I Suárez; E J Perea
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

2.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Authors:  F Tessier; C Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

3.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Antibacterial spectrum of fosfomycin trometamol.

Authors:  A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

5.  Single-dose fosfomycin trometamol versus multiple-dose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners.

Authors:  P Crocchiolo
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

6.  Fosfomycin trometamol versus amoxycillin--single-dose multicenter study of urinary tract infections.

Authors:  H C Neu
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

Review 7.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

8.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections.

Authors:  Z de Jong; F Pontonnier; P Plante
Journal:  Urol Int       Date:  1991       Impact factor: 2.089

10.  In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.

Authors:  Anna Marchese; Laura Gualco; Eugenio A Debbia; Gian Carlo Schito; Anna Maria Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  31 in total

1.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 2.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

3.  Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.

Authors:  Elizabeth C Smith; Hunter V Brigman; Jadyn C Anderson; Christopher L Emery; Tiffany E Bias; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

Review 4.  The Use of Antibiotic Impregnated Cement Spacers in the Treatment of Infected Total Joint Replacement: Challenges and Achievements.

Authors:  Omid Shahpari; Alireza Mousavian; Nafise Elahpour; Michael-Alexander Malahias; Mohammad H Ebrahimzadeh; Ali Moradi
Journal:  Arch Bone Jt Surg       Date:  2020-01

5.  Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) P. Aeruginosa Isolated from Patients in Tehran, Iran.

Authors:  Horieh Saderi; Parviz Owlia
Journal:  Iran J Pathol       Date:  2015

Review 6.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

7.  Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

Authors:  L V Perdigão-Neto; M S Oliveira; C F Rizek; C M D M Carrilho; S F Costa; A S Levin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

8.  Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.

Authors:  Marina Borisova; Jonathan Gisin; Christoph Mayer
Journal:  Microb Drug Resist       Date:  2014-05-12       Impact factor: 3.431

9.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

10.  Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli.

Authors:  Qinglan Guo; Adam D Tomich; Christi L McElheny; Vaughn S Cooper; Nicole Stoesser; Minggui Wang; Nicolas Sluis-Cremer; Yohei Doi
Journal:  J Antimicrob Chemother       Date:  2016-06-03       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.